From the American Academy of Ophthalmology

This post hoc analysis of an open-label clinical trial considered 20 patients with branch retinal vein occlusion (BRVO) and 20 with central retinal vein occlusion (CRVO)who received ranibizumab monthly for three months and as needed for recurrent/persistent macular edema, no more frequently than every two months. Edema resolved from injections alone in 45 percent of BRVO patients after a mean of 6.4 injections over 20.2 months, and in 25 percent of CRVO patients after a mean of 14 months. In both BRVO and CRVO, there was a negative correlation between posterior retinal nonperfusion area and BCVA through three years of follow-up (P < .05). American Journal of Ophthalmology, October 2013